Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 8Active not recruiting 3

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3

Interventions

Carboplatin 18Cisplatin 14pembrolizumab 13durvalumab 11Pemetrexed 11Paclitaxel 11Nivolumab 11Gemcitabine 11Rituximab 9trastuzumab deruxtecan 7osimertinib 6olaparib 6Dexamethasone 6Capecitabine 6atezolizumab 5acalabrutinib 5Specimen Handling 5Lenalidomide 5Bevacizumab 5130-nm albumin-bound paclitaxel 5tremelimumab 4niraparib 4cabozantinib 4amivantamab 4Prednisone 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fulvestrant 4Docetaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Has announcements × daratumumab × Clear all
NCT05083169 2026-05-08

MajesTEC-3

Janssen Research & Development, LLC

Phase 3 Active not recruiting
587 enrolled 1 FDA
Plasma cell

Multiple Myeloma

NCT04246047 2026-04-23

DREAMM 7

GlaxoSmithKline

Phase 3 Active not recruiting
494 enrolled 10 charts 1 FDA
Plasma cell

Multiple Myeloma

NCT03710603 2026-02-10

Perseus

European Myeloma Network B.V.

Phase 3 Active not recruiting
709 enrolled 17 charts 1 FDA
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡